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Abstract. Vanadium is a grey metal, existing in different 
states of oxidation, whose most common form in commer-
cial products is vanadium pentoxide (V2O5). All vanadium 
compounds have been considered toxic. A carcinogenic role of 
vanadium on the thyroid has recently been proposed. However 
no in vivo or in vitro studies have evaluated thyroid disruption 
in humans and/or animals after exposure to vanadium. In the 
present study we evaluate the effect of V2O5 on proliferation, 
and chemokine secretion in normal thyrocytes. Our study 
demonstrated that V2O5 has no effect on thyroid follicular cell 
viability or proliferation, but it is able to induce the secretion 
of T-helper (Th)1 chemokines into the thyroid, synergistically 
increasing the effect of important Th1 cytokines such as 
interferon (IFN)γ and tumor necrosis factor (TNF)α. Through 
this process, V2O5 promotes the induction and perpetuation 
of an inflammatory reaction in the thyroid. Further studies 
are necessary to evaluate thyroid function, and nodules, in 
subjects occupationally exposed, or living in polluted areas.
Introduction
Vanadium is a grey metal that exists in a number of different 
states of oxidation: -1, 0, +2, +3, +4 and +5. The most common 
form in commercial products is vanadium pentoxide (V2O5). 
All vanadium compounds have been considered toxic. The 
maximum amount of human V2O5 exposure has been estab-
lished by the Occupational Safety and Health Administration 
of the US Department of Labor as 0.05 mg/m3 for dust and 
0.1 mg/m3 for fumes, in workplace air for an 8 h workday/40 h 
work week (1). Exposure to a 35 mg/m3 dose of vanadium is 
considered life-threatening and could provoke serious and 
perpetual health issues including death, as determined by The 
National Institute for Occupational Safety and Health (1).
The respiratory system is the most vulnerable system to 
the toxic effect of vanadium whereas there is inconsequential 
action on the gastrointestinal system due to the minimal gut 
absorption rate of the substance (2-4). Unfortunately, we 
lack satisfactory data to determine the reference range of a 
subchronic or chronic inhaled dose. The effects resulting 
from an oral or inhaled vanadium exposure on serum param-
eters (5,6), the liver (7), nervous system (8) and development of 
other tissues have been described in rat models (9).
Recently, the increase in the incidence of thyroid cancer 
in areas of volcanic activity suggest a carcinogenic effect of 
volcanic pollution. In the Mount Etna volcanic area, the inci-
dence of thyroid cancer was higher than that in control areas 
(18.5 and 9.6/105 inhabitants, respectively). In volcanic areas, 
various trace elements are increased (with respect to control 
areas) in both lichens and drinking water, indicating atmo-
spheric and water pollution. The amounts of trace elements 
are significantly increased, among them vanadium which was 
increased 8 times, and its possible carcinogenic role on the 
thyroid has been hypothesized (10,11).
However, no in vivo or in vitro studies have evaluated 
thyroid/endocrine disruption in humans and/or animals after 
exposure to vanadium. In the present study, we evaluated the 
effect of V2O5 on the proliferation and chemokine secretion of 
normal thyrocytes.
Materials and methods
Thyroid follicular cells (TFCs). We collected 10 specimens of 
thyroid tissue from 10 euthyroid patients (mean age, 41 years, 
range 24-61; 5 females, 5 males) (8 undergoing parathyroid-
ectomy, 2 laryngeal intervention). We obtained informed 
consent from all participants, and the local ethics committee 
of the University of Pisa provided approval for the study. 
Thyrocytes were prepared as previously described (12-14). 
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The digestion of tissue samples was carried out by collagenase 
(Roche Diagnostics GmbH, Mannheim, Germany; 1 mg/ml) 
with RPMI-1640 (Whittaker Bioproducts, Inc., Walkersville, 
MD, USA) for 1 h at 37̊C. The semi-digested follicles were 
removed and sedimented for 2 min; they were then washed 
and cultured with RPMI-1640 medium in the presence of 
fetal bovine serum (FBS) 10% (Seromed Biochrome, Berlin, 
Germany), 50 mg/ml penicillin/streptomycin, 2 mM gluta-
mine, with 5% CO2 at 37̊C.
Cell viability and proliferation assay. Cell viability and prolif-
eration were evaluated using the WST-1 (Roche Diagnostics, 
Almere, The Netherlands) assay (which uses 3-[4,5-dimeth-
ylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, in the MTT 
assay) (15-17). TFCs were seeded at a density of 35,000 cells/ml 
(in a final volume of 100 µl) in each well of 96-well plates. To 
determine how V2O5 affects TFC proliferation, the cells were 
treated (24 h) with increasing concentrations of V2O5 (1, 10 
and 100 nM). For each cell preparation, the experiments were 
performed in triplicate. Cells were plated and treated for 24 h 
with V2O5 or with its vehicle alone.
Proliferation assay: Cell counting. Cell number counting was 
also used to evaluate the proliferation of TFCs as previously 
described (15-17).
Chemokine secretion assays. To successfully perform the 
chemokine (C-X-C motif) ligand (CXCL)9, or CXCL10 
secretion assays, 30,000 cells/ml were seeded (in 96-well 
plates) in a final volume of 100 µl/well, in growth medium, 
which was then removed (after 24 h). Cells were then washed 
with phosphate-buffered saline (PBS) and incubated (for 
24 h) in serum and phenol red-free medium with interferon 
(IFN)γ (500, 1,000, 5,000 and 10,000 IU/ml; R&D Systems, 
Minneapolis, MN, USA) and tumor necrosis factor (TNF)
α (10 ng/ml) (R&D Systems), in combination (13) or alone. 
The TNFα concentration was chosen to obtain the highest 
secretion in preliminary experiments. The supernatant was 
then obtained (after 24 h), and kept frozen at -20̊C (until 
chemokine assay).
To understand how V2O5 affects the chemokine secre-
tion induced by IFNγ, the cells were treated (for 24 h) with 
increasing concentrations of V2O5 (1, 10 and 100 nM), in 
the presence/absence of IFNγ (1,000 IU/ml) and/or TNFα 
(10 ng/ml). CXCL9 and CXCL10 in the supernatants were 
measured by ELISA. The experiments were conducted 3 times 
with each different cell preparation.
ELISA for CXCL9 and CXCL10. CXCL9 or CXCL10 was 
assessed in the supernatants from cell cultures by commer-
cially prepared kits (R&D Systems). The minimum (mean) 
detectable doses were 1.5 or 1.2 pg/ml, for CXCL9, or CXCL10 
(respectively). The intra- and inter-assay coefficients of varia-
tion were for 3.5 and 6.4%, respectively, for CXCL9, while 
these coefficients for CXCL10 were 4.5 and 7.3%, respectively. 
Quality control pools of normal, low and high concentrations 
were also included in each assay.
Data analysis. For normally distributed variables, the values 
are expressed in the text as mean (± SD), or mean (± SEM) in 
figures, otherwise as median [and interquartile range]. Mean 
group values were compared by using one-way analysis of 
variance (ANOVA) for variables normally distributed, or with 
the Kruskal-Wallis test, or Mann-Whitney U test. Proportions 
were compared by the Chi-square test. The Bonferroni-Dunn 
test was used for post hoc comparison of normally distributed 
variables.
Results
Cell proliferation. Cell viability and proliferation assay WST-1 
demonstrated that V2O5 (1, 10 and 100 nM) did not alter the 
viability or proliferation of the TFCs (Fig. 1). These results 
were confirmed by cell counting (data not shown).
CXCL9. CXCL9 levels were not detectable in supernatants 
gathered from primary thyrocyte samples, whereas the CXCL9 
concentration was increased after dose-dependent induction 
of IFNγ (0, 61±27, 136±34, 196±41 and 262±67 pg/ml; with 
IFNγ 0, 500, 1,000, 5,000 and 10,000 IU/ml, respectively; 
P<0.001 by ANOVA). TNFα alone was not able to promote 
any impact on CXCL9 (remaining undetectable), while the 
synergy of IFNγ plus TNFα elicited a significant influence on 
CXCL9 release (CXCL9, 8976±1456 vs. 142±34 pg/ml with 
IFNγ alone, P<0.0001 by ANOVA).
Following the treatment of thyrocytes with V2O5 (1, 10 
and 100 nM), CXCL9 secretion was dose-dependently stimu-
lated (ANOVA, P<0.0001) (Fig. 2A). Following the treatment 
of thyrocytes with V2O5 (1, 10 and 100 nM), together with 
TNFα, CXCL9 secretion was not significantly altered with 
respect to V2O5 alone (data not shown).
Following the treatment of thyrocytes with V2O5 (100 nM), 
together with IFNγ, CXCL9 release was synergistically 
increased (ANOVA, P<0.0001) (Fig. 3A).
Following the treatment of thyrocytes with V2O5 (100 nM), 
together with IFNγ and TNFα, CXCL9 secretion was syner-
gistically increased (ANOVA, P<0.0001) (Fig. 4A).
Figure 1. Cell viability and proliferation assay WST-1 showed that V2O5 
(V2O5; 1, 10 and 100 nM) did not alter the viability or proliferation of TFCs 
[mean group values are compared by using one-way analysis of variance 
(ANOVA); the Bonferroni-Dunn test was used for post hoc comparison; 
P>0.05, for all comparisons].
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CXCL10. CXCL10 was not detectable in the supernatants from 
primary thyrocyte cultures in basal condition. IFNγ induced 
CXCL10 secretion dose-dependently (0, 45±22, 111±35, 
213±27, 254±64 pg/ml, with IFNγ 0, 500, 1,000, 5,000 and 
10,000 IU/ml; respectively; P<0.001 by ANOVA). TNFα only 
was not able in this case to carry out any impact on CXCL10, 
while the synergy of IFNγ plus TNFα elicited a significant 
influence on CXCL10 secretion (2,011±154 vs. 108±26 pg/ml 
with IFNγ alone; P<0.0001, by ANOVA).
Following treatment of thyrocytes with V2O5 (1, 10 and 
100 nM) CXCL10 secretion was stimulated dose-dependently 
(P<0.0001 by ANOVA) (Fig. 2B). Following treatment of 
thyrocytes with V2O5 (1, 10 and 100 nM), together with TNFα, 
CXCL10 secretion was not significantly changed with respect 
to V2O5 alone (data not shown).
Following treatment of thyrocytes with V2O5 (100 nM), 
together with IFNγ, CXCL10 release was synergistically 
increased (P<0.0001 by ANOVA) (Fig. 3B).
Following treatment of thyrocytes with V2O5 (100 nM), 
together with IFNγ plus TNFα, CXCL10 secretion was syner-
gistically increased (P<0.0001 by ANOVA) (Fig. 4B).
Discussion
The results of the present study demonstrated that V2O5 can 
promote IFNγ-dependent chemokine secretion by TFCs, 
without altering the viability and proliferation of the cells. 
Moreover, as expected (14), our study confirmed that IFNγ and 
TNFα stimulated the secretion of C-X-C chemokines, CXCL9 
and CXCL10, evaluated by ELISA, which is an accepted and 
commonly published method to dose chemokine levels in 
supernatants. Notably, V2O5 was able to synergize with IFNγ 
and TNFα, further increasing chemokine secretion. These 
results, on the whole, are in agreement with the view that V2O5 
is able to induce and perpetuate an inflammatory disorder 
in the thyroid evolving from a predominant T-helper (Th)1 
immune response (15).
In fact, IFNγ-inducible C-X-C chemokines can be secreted 
by several types of mammalian cells, such as fibroblasts, 
thyrocytes, islet cells, colon epithelial cells, endothelial cells, 
and others (12-19). However, in basal condition such cell types 
do not produce these chemokines, that are secreted after the 
stimulation with IFNγ (alone or in combination with TNFα), 
a cytokine that is produced by Th1-activated lymphocytes in 
Figure 2. (A) Following treatment of thyrocytes with V2O5 (V2O5; 1, 10 and 
100 nM), CXCL9 secretion was dose-dependently stimulated (P<0.0001, by 
ANOVA). (B) Following treatment of thyrocytes with V2O5 (V2O5; 1, 10 and 
100 nM), CXCL10 secretion was dose-dependently stimulated (P<0.0001, by 
ANOVA) (Bonferroni-Dunn test was used for post hoc comparison; *P<0.05).
Figure 3. (A) Following treatment of thyrocytes with V2O5 (V2O5; 
10 0 nM) + IF Nγ  ( IF N),  CXCL9 release was synergist ica l ly 
increased (P<0.0001, by ANOVA). (B) Following treatment of thyrocytes 
with V2O5 (V2O5; 100 nM) + IFNγ (IFN), CXCL10 release was synergisti-
cally increased (P<0.0001, by ANOVA) (Bonferroni-Dunn test was used for 
post hoc comparison; *P<0.05 vs. control; **P<0.05 vs. IFN or V2O5).
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several autoimmune diseases, for example in the thyroid in 
Graves' disease, or in autoimmune thyroiditis. This process 
has been hypothesized to be involved in the initiation and/or 
the perpetuation in several autoimmune disorders (12-21), and 
it can be applied also to the thyroid.
Our results agree with those of other researches in different 
cell types. V2O5 exposure is a cause of occupational bronchitis, 
and a study evaluated gene expression profiles in human lung 
fibroblasts (in cultures) after exposure in vitro to V2O5 in 
order to identify genes that may play a role in the bronchial 
inflammation, repair and fibrosis in the pathogenesis of bron-
chitis. Approximately 12 genes were overexpressed following 
exposure to V2O5, including chemokines (CXCL9, CXCL10 
and interleukin-8) (22). In a second study, it was shown that 
fibroblasts respond to vanadium oxidative stress by producing 
IFNβ and activating STAT-1, that led to increased CXCL10 
levels (23), playing a role in the innate immune response.
Importantly, vanadium was able to increase chemokine 
secretion in a dose range, from 1 to 100 nM. It was observed 
that normal blood levels of vanadium range from 0.45 to 
18.4 nM, and that 100 nM is a dose that may mimic an abnor-
mally high exposure (24).
The mechanisms by which V2O5 induces lung cancer have 
been investigated in mice in numerous studies. Experts agree 
that in vivo and in vitro research suggests that cancers are 
induced by secondary mechanisms (probably not genotoxic 
effects) (25).
Thus, we hypothesized that, also for the thyroid, the 
induction and perpetuation of an inflammatory reaction into 
this gland, and the variety of involved candidate genes could 
predispose to the appearance of thyroid cancer (as recently 
demonstrated for the association of papillary thyroid cancer 
and autoimmune thyroiditis), and could be at the basis of 
V2O5-induced effects after occupational and environmental 
exposure.
In conclusion, the present study showed that V2O5 is able 
to induce the secretion of Th1 chemokines into the thyroid, 
synergistically increasing the effect of important Th1 cyto-
kines such as IFNγ and TNFα, leading to the induction and 
perpetuation of an inflammatory reaction in the thyroid. 
Further studies are necessary to investigate the mechanism 
of action by which chemokines are secreted, and to evaluate 
thyroid function, and nodules, in subjects occupationally 
exposed, or living in polluted areas.
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